Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SPM-0404
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : IND Enabling
Sponsor : TCG Lifesciences
Deal Size : Undisclosed
Deal Type : Collaboration
Sea Pharmaceuticals Progresses Oral Neurotherapeutics with TCG GreenChem
Details : The collaboration aims to advance Sea's lead molecule SPM-0404 and a second-generation molecule SPM-0606, biologically active as dual AMPAR, KAINR antagonists.
Brand Name : SPM-0404
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 14, 2024
Lead Product(s) : SPM-0404
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : IND Enabling
Sponsor : TCG Lifesciences
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?